  | |
| Education | : | Ph.D., Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University (2009-2014)
Master, Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University (2006-2009)
Bachelor of Science, Pharmacy, School of Pharmacy, College of Medicine, National Taiwan University (2002-2006) | | Experience | : | Institute of Biomedical Sciences, Academia Sinica, Postdoctoral research fellow 2015.09.01~2017.07.31
Department of Medical Research,National Taiwan University Hospital,Postdoctoral research fellow 2014.10.1~2015.7.31 | | Honor | : | 2015.03 Outstanding academic performances scholarship, Association of Taipei City Residents from Chiayi
2009-2014 Scholarships and Assistantships, Institute of Cellular and System Medicine, National Health Research Institute (NHRI)
2014.10 Best Poster Awards, honorable mention, Taiwan Society for Stem Cell Research
2014.07 Best Poster Awards, the third place prize, the Fifth Annual Institutes of Clinical Medicine Joint Research and Teaching Workshop
2013.04 Outstanding Research Award, NHRI
2008.06 Outstanding Student, Graduate Institute of Clinical Pharmacy, NTU
2008.06 Honorary member of The Phi Tau Phi Scholastic Honor Society
2006.09 The first place in Senior Professional and Technical Examinations for Pharmacist
2006.06 Honorary member of The Phi Tau Phi Scholastic Honor Society
2006.06 New Graduate Outstanding Award, the first place prize, NTU
2006.06 New Graduate Service Medal, NTU
2006.06 New Graduate Distinguished Achievement Award in hospital pharmacy practice experience, NTU
2006.03 Academic Achievement Award, NTU
2005.10 Academic Achievement Award, NTU
2005.04 Academic Achievement Award, NTU
2004.10 Academic Achievement Award, NTU
2004.04 Academic Achievement Award, NTU
2003.10 Academic Achievement Award, NTU
| | Research Areas | : | Clinical pharmacy, Immunology, Cardiology, Stem cell translational research | | Lab Focus | : | Metabolic syndrome (MetS), characterized by a variety of clinical manifestations including abdominal obesity, insulin resistance, hypertension, and dyslipidemia, is associated with an increased risk of cardiovascular diseases.
Adipose tissue (AT) plays a central role in the development of MetS. The production of proinflammatory cytokines in visceral AT tends to induce a low-grade systemic inflammation, termed metaflammation, and contributes to metabolic abnormalities. Accordingly, anti-inflammation therapy, a strategy targeting the pathogenic mechanism of MetS, is mandatory.
Residing in AT, ASCs are clinically attractive owing to their immunomodulatory potential; however, ASCs can be beneficial or detrimental to health depending on the environment conditions. ASCs furnish a new paradigm for screening signaling molecules in an obesity-relevant context, and will play a significant role in ushering the era of immunomodulation in metaflammation-associated diseases. ASCs under the influence of obesity-derived factors possess properties that distinguish them from ASCs isolated from a lean individual, namely, decreased quantities and impaired anti-inflammation. We hypothesize that boost immunomodulatory capability of ASCs will compensate their shortage in obesity, thus protecting from metaflammation-induced detrimental effects.
Our research seeks to synergize in stem cell biology, immunobiology, transcriptome analysis, animal models for MetS and obesity, and molecular screening and profiling for drug development in a unique manner, in order to build a platform that has strong potential to create academic and medical impact on both the domestic and international stages. Ultimately, we expect that the knowledge gained from using the ASCs platform will enable and accelerate the discovery of better immunomodulatory drugs, and enable clinicians to better prescribe therapeutic strategies for MetS and obese patients in the future.
| | Research Subjects | : | 1. Screen of butyrate derivatives to prime adipose-derived stem cells
for enhanced cardioprotective effects (NTU-KPU
collaboration)
2. Explore the novel immunomodulatory molecules for preventing heart failure after MI or cancer therapy-related cardiac dysfunction
3. Drug-related problems and the roles of clinical pharmacists in the multidisciplinary team intervention in heart failure | | Teacher's Word | : | Clinical pharmacy scientist career is whatever you make of it, as long as you try. | | Lab Requirements | : | Waste no second, and let every step we take be solid ones. |
|
